Nick C Fox

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5583295/publications.pdf Version: 2024-02-01



NICK C FOX

#	Article	IF	CITATIONS
1	Biomarker clustering in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2023, 19, 274-284.	0.8	2
2	Cerebrospinal fluid metallomics in cerebral amyloid angiopathy: an exploratory analysis. Journal of Neurology, 2022, 269, 1470-1475.	3.6	5
3	Variability in the type and layer distribution of cortical Aβ pathology in familial Alzheimer's disease. Brain Pathology, 2022, 32, e13009.	4.1	12
4	A data-driven disease progression model of fluid biomarkers in genetic frontotemporal dementia. Brain, 2022, 145, 1805-1817.	7.6	27
5	Stratifying the Presymptomatic Phase of Genetic Frontotemporal Dementia by Serum <scp>NfL</scp> and <scp>pNfH</scp> : A Longitudinal Multicentre Study. Annals of Neurology, 2022, 91, 33-47.	5.3	21
6	Different rates of cognitive decline in autosomal dominant and lateâ€onset Alzheimer disease. Alzheimer's and Dementia, 2022, 18, 1754-1764.	0.8	4
7	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	6.2	4
8	Association of <i>BDNF</i> Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease. JAMA Neurology, 2022, 79, 261.	9.0	15
9	Practical application of Alzheimer's Disease Neuroimaging Initiative plasma Pâ€ŧau181 reference data to support diagnosis of Alzheimer's disease. International Journal of Geriatric Psychiatry, 2022, 37, .	2.7	1
10	Variant-dependent heterogeneity in amyloid β burden in autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurology, The, 2022, 21, 140-152.	10.2	34
11	Amyloid processing in <scp>COVID</scp> â€19â€associated neurological syndromes. Journal of Neurochemistry, 2022, 161, 146-157.	3.9	35
12	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	2.4	2
13	Conceptual framework for the definition of preclinical and prodromal frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 1408-1423.	0.8	24
14	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	3.1	1
15	Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities. Frontiers in Neuroscience, 2022, 16, 835645.	2.8	10
16	Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer's disease. Nature Communications, 2022, 13, 1495.	12.8	11
17	The <scp>CBIâ€R</scp> detects early behavioural impairment in genetic frontotemporal dementia. Annals of Clinical and Translational Neurology, 2022, 9, 644-658.	3.7	1
18	Characterizing Heterogeneity in Neuroimaging, Cognition, Clinical Symptoms, and Genetics Among Patients With Late-Life Depression. JAMA Psychiatry, 2022, 79, 464.	11.0	47

#	Article	IF	CITATIONS
19	CSF biomarkers for dementia. Practical Neurology, 2022, 22, 285-294.	1.1	3
20	Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study. Lancet Neurology, The, 2022, 21, 329-341.	10.2	72
21	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
22	Aβ profiles generated by Alzheimer's disease causing PSEN1 variants determine the pathogenicity of the mutation and predict age at disease onset. Molecular Psychiatry, 2022, 27, 2821-2832.	7.9	37
23	Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease. NeuroImage, 2022, 256, 119228.	4.2	27
24	Associations of β-Amyloid and Vascular Burden With Rates of Neurodegeneration in Cognitively Normal Members of the 1946 British Birth Cohort. Neurology, 2022, 99, .	1.1	12
25	Combining navigator and optical prospective motion correction for <scp>highâ€quality</scp> 500 μm resolution quantitative <scp>multiâ€parameter</scp> mapping at <scp>7T</scp> . Magnetic Resonance in Medicine, 2022, 88, 787-801.	3.0	12
26	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurology, 2022, 79, 592.	9.0	29
27	Alzheimer's Disease Biomarkers Revisited From the Amyloid Cascade Hypothesis Standpoint. Frontiers in Neuroscience, 2022, 16, 837390.	2.8	12
28	Autosomal dominant and sporadic late onset Alzheimer's disease share a common <i>in vivo</i> pathophysiology. Brain, 2022, 145, 3594-3607.	7.6	20
29	Pure tone audiometry and cerebral pathology in healthy older adults. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A9.1-A9.	1.9	0
30	Imaging tau pathology in Alzheimer's disease with positron emission tomography: lessons learned from imaging-neuropathology validation studies. Molecular Neurodegeneration, 2022, 17, .	10.8	5
31	Association between carotid atherosclerosis and brain activation patterns during the Stroop task in older adults: An fNIRS investigation. NeuroImage, 2022, 257, 119302.	4.2	3
32	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. NeuroImage: Clinical, 2022, 35, 103106.	2.7	9
33	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	7.9	76
34	Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease. Biological Psychiatry, 2021, 89, 776-785.	1.3	30
35	The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 614-628.	7.9	61
36	A Clinicopathologic Study of Movement Disorders in Frontotemporal Lobar Degeneration. Movement Disorders, 2021, 36, 632-641.	3.9	3

NICK C FOX

#	Article	IF	CITATIONS
37	Genetic testing in dementia — utility and clinical strategies. Nature Reviews Neurology, 2021, 17, 23-36.	10.1	26
38	A critical review of the epidemiological evidence of effects of air pollution on dementia, cognitive function and cognitive decline in adult population. Science of the Total Environment, 2021, 757, 143734.	8.0	110
39	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.8	36
40	Mild Cognitive Impairment: the Manchester consensus. Age and Ageing, 2021, 50, 72-80.	1.6	80
41	Impairment of episodic memory in genetic frontotemporal dementia: A GENFI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12185.	2.4	11
42	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. European Radiology, 2021, 31, 5312-5323.	4.5	19
43	Progression of Behavioral Disturbances and Neuropsychiatric Symptoms in Patients With Genetic Frontotemporal Dementia. JAMA Network Open, 2021, 4, e2030194.	5.9	42
44	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12131.	2.4	19
45	Discriminatory ability of next-generation tau PET tracers for Alzheimer's disease. Brain, 2021, 144, 2284-2290.	7.6	29
46	A populationâ€based study of head injury, cognitive function and pathological markers. Annals of Clinical and Translational Neurology, 2021, 8, 842-856.	3.7	5
47	Segregation of functional networks is associated with cognitive resilience in Alzheimer's disease. Brain, 2021, 144, 2176-2185.	7.6	66
48	Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	7.6	16
49	Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease. Brain Connectivity, 2021, 11, 239-249.	1.7	18
50	Eye-tracking indices of impaired encoding of visual short-term memory in familial Alzheimer's disease. Scientific Reports, 2021, 11, 8696.	3.3	10
51	Investigating the relationship between BMI across adulthood and late life brain pathologies. Alzheimer's Research and Therapy, 2021, 13, 91.	6.2	7
52	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. Alzheimer's and Dementia, 2021, 17, 1189-1204.	0.8	44
53	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology, 2021, 78, 396.	9.0	146
54	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	1.3	10

#	Article	IF	CITATIONS
55	Subjective cognitive complaints at age 70: associations with amyloid and mental health. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1215-1221.	1.9	16
56	KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer's disease. Nature Communications, 2021, 12, 3825.	12.8	29
57	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	6.0	54
58	The Revised Self-Monitoring Scale detects early impairment of social cognition in genetic frontotemporal dementia within the GENFI cohort. Alzheimer's Research and Therapy, 2021, 13, 127.	6.2	12
59	Same data, different conclusions: Radical dispersion in empirical results when independent analysts operationalize and test the same hypothesis. Organizational Behavior and Human Decision Processes, 2021, 165, 228-249.	2.5	51
60	A novel presenilin 1 duplication mutation (lle168dup) causing Alzheimer's disease associated with myoclonus, seizures and pyramidal features. Neurobiology of Aging, 2021, 103, 137.e1-137.e5.	3.1	1
61	Donanemab removes Alzheimer's plaques: what is special about its target?. The Lancet Healthy Longevity, 2021, 2, e395-e396.	4.6	5
62	Suspecting dementia: canaries, chameleons and zebras. Practical Neurology, 2021, 21, 300-312.	1.1	13
63	Reply: Functional cognitive disorder: dementia's blind spot. Brain, 2021, 144, e73.	7.6	2
64	Accelerated functional brain aging in pre-clinical familial Alzheimer's disease. Nature Communications, 2021, 12, 5346.	12.8	43
65	Sex-related differences in whole brain volumes at age 70 in association with hyperglycemia during adult life. Neurobiology of Aging, 2021, 112, 161-169.	3.1	1
66	Regional Age-Related Atrophy After Screening for Preclinical Alzheimer Disease. Neurobiology of Aging, 2021, 109, 43-51.	3.1	9
67	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. Translational Psychiatry, 2021, 11, 483.	4.8	23
68	Visual short-term memory impairments in presymptomatic familial Alzheimer's disease: A longitudinal observational study. Neuropsychologia, 2021, 162, 108028.	1.6	7
69	Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease. Brain Communications, 2021, 3, fcab003.	3.3	8
70	Modeling autosomal dominant Alzheimer's disease with machine learning. Alzheimer's and Dementia, 2021, 17, 1005-1016.	0.8	12
71	Differential early subcortical involvement in genetic FTD within the GENFI cohort. NeuroImage: Clinical, 2021, 30, 102646.	2.7	28
72	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	2.7	8

#	Article	IF	CITATIONS
73	Familial Alzheimer's Disease Mutations in PSEN1 Lead to Premature Human Stem Cell Neurogenesis. Cell Reports, 2021, 34, 108615.	6.4	53
74	Longitudinal Accumulation of Cerebral Microhemorrhages in Dominantly Inherited Alzheimer Disease. Neurology, 2021, 96, e1632-e1645.	1.1	16
75	OUP accepted manuscript. Brain, 2021, 144, 434-449.	7.6	54
76	Dissociable effects of APOE ε4 and β-amyloid pathology on visual working memory. Nature Aging, 2021, 1, 1002-1009.	11.6	16
77	Tauâ€Atrophy Variability Reveals Phenotypic Heterogeneity in Alzheimer's Disease. Annals of Neurology, 2021, 90, 751-762.	5.3	19
78	Losartan to slow the progression of mild-to-moderate Alzheimer's disease through angiotensin targeting: the RADAR RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-72.	0.7	3
79	Loss and dispersion of superficial white matter in Alzheimer's disease: a diffusion MRI study. Brain Communications, 2021, 3, fcab272.	3.3	18
80	A panel of CSF proteins separates genetic frontotemporal dementia from presymptomatic mutation carriers: a GENFI study. Molecular Neurodegeneration, 2021, 16, 79.	10.8	9
81	A deep learning framework identifies dimensional representations of Alzheimer's Disease from brain structure. Nature Communications, 2021, 12, 7065.	12.8	38
82	Prediction of amyloid pathology in cognitively unimpaired individuals using structural MRI. Alzheimer's and Dementia, 2021, 17, .	0.8	0
83	Disentangling axonal loss and demyelination using multiâ€modal imaging: Application to young onset Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
84	Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Molecular Psychiatry, 2020, 25, 3399-3412.	7.9	34
85	Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. Molecular Psychiatry, 2020, 25, 2919-2931.	7.9	99
86	Associations Between Vascular Risk Across Adulthood and Brain Pathology in Late Life. JAMA Neurology, 2020, 77, 175.	9.0	55
87	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
88	Longitudinal (¹⁸ F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 106-108.	1.9	8
89	Disease duration in autosomal dominant familial Alzheimer disease. Neurology: Genetics, 2020, 6, e507.	1.9	13
90	Single-subject grey matter network trajectories over the disease course of autosomal dominant Alzheimer's disease. Brain Communications, 2020, 2, fcaa102.	3.3	11

#	Article	lF	CITATIONS
91	Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration. Molecular Neurodegeneration, 2020, 15, 57.	10.8	33
92	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
93	BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. Brain, 2020, 143, 3816-3826.	7.6	41
94	Neuronal intranuclear inclusion disease is genetically heterogeneous. Annals of Clinical and Translational Neurology, 2020, 7, 1716-1725.	3.7	38
95	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	3.3	4
96	Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, The, 2020, 396, 413-446.	13.7	4,658
97	Increased variability in reaction time is associated with amyloid beta pathology at age 70. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12076.	2.4	8
98	Functional cognitive disorder: dementia's blind spot. Brain, 2020, 143, 2895-2903.	7.6	84
99	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis. Alzheimer's Research and Therapy, 2020, 12, 126.	6.2	13
100	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 112.	6.2	18
101	Analysis of brain atrophy and local gene expression in genetic frontotemporal dementia. Brain Communications, 2020, 2, .	3.3	20
102	Plasma phosphoâ€tau181 in over 400 cognitively healthy 69†to 71â€yearâ€olds: Associations with cerebral amyloid, structural imaging and cognition in the Insight 46 study. Alzheimer's and Dementia, 2020, 16, e037848.	0.8	0
103	Vascular risk factors and amyloid pathology: Additive or interactive associations?. Alzheimer's and Dementia, 2020, 16, e037922.	0.8	0
104	White matter hyperintensity increases are a feature of familial AD and are associated with increased brain atrophy. Alzheimer's and Dementia, 2020, 16, e038925.	0.8	0
105	Predicting Alzheimer's disease progression: Results from the TADPOLE Challenge. Alzheimer's and Dementia, 2020, 16, e039538.	0.8	9
106	Disease duration in autosomal dominant familial Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039738.	0.8	0
107	Uncovering superficial white matter changes in youngâ€onset Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e039746.	0.8	0
108	Premature neuronal differentiation in familial Alzheimer's disease human stem cells in vitro and in postmortem brain tissue. Alzheimer's and Dementia, 2020, 16, e039793.	0.8	0

#	Article	IF	CITATIONS
109	Performance on the graded naming test in a populationâ€based sample of 72â€yearâ€olds: Associations with lifeâ€course predictors and βâ€amyloid pathology. Alzheimer's and Dementia, 2020, 16, e040897.	0.8	0
110	Accelerated forgetting is sensitive to βâ€amyloid pathology and cerebral atrophy in cognitively normal 72â€yearâ€olds. Alzheimer's and Dementia, 2020, 16, e040987.	0.8	0
111	APOEâ€Îµ4 carriers have superior recall on the †What was where?' visual shortâ€ŧerm memory binding test at age 70, despite a detrimental effect of βâ€amyloid. Alzheimer's and Dementia, 2020, 16, e041090.	0.8	4
112	Lifetime cigarette smoking and laterâ€life brain health: The populationâ€based 1946 British Birth Cohort. Alzheimer's and Dementia, 2020, 16, e041111.	0.8	1
113	Amyloid Pattern Similarity Score (AMPSS): A reference region free measure of amyloid PET deposition in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042673.	0.8	2
114	Plasma phosphoâ€ŧau in familial Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042921.	0.8	0
115	Cerebral amyloid and white matter hyperintensity volume are independently associated with rates of cerebral atrophy in Insight 46, a subâ€study of the 1946 British birth cohort. Alzheimer's and Dementia, 2020, 16, e044924.	0.8	0
116	Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET. Alzheimer's and Dementia, 2020, 16, e045991.	0.8	0
117	Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12097.	2.4	5
118	How to diagnose difficult white matter disorders. Practical Neurology, 2020, 20, 280-286.	1.1	3
119	A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nature Medicine, 2020, 26, 398-407.	30.7	351
120	Non-memory led dementias: care in the time of covid-19. BMJ, The, 2020, 369, m2489.	6.0	7
121	Olfactory testing does not predict β-amyloid, MRI measures of neurodegeneration or vascular pathology in the British 1946 birth cohort. Journal of Neurology, 2020, 267, 3329-3336.	3.6	4
122	Imaging biomarkers in neurodegeneration: current and future practices. Alzheimer's Research and Therapy, 2020, 12, 49.	6.2	96
123	Pure tone audiometry and cerebral pathology in healthy older adults. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 172-176.	1.9	16
124	The Dementias Platform UK (DPUK) Data Portal. European Journal of Epidemiology, 2020, 35, 601-611.	5.7	45
125	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease, 2020, 74, 1189-1201.	2.6	38
126	Faster Cortical Thinning and Surface Area Loss in Presymptomatic and Symptomatic <i>C9orf72</i> Repeat Expansion Adult Carriers. Annals of Neurology, 2020, 88, 113-122.	5.3	19

#	Article	IF	CITATIONS
127	Amyloid β influences the relationship between cortical thickness and vascular load. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12022.	2.4	7
128	Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's diseaseâ€informed machineâ€learning. Alzheimer's and Dementia, 2020, 16, 501-511.	0.8	47
129	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	2.4	26
130	Study Protocol — Insight 46 Cardiovascular: A Sub-study of the MRC National Survey of Health and Development. Artery Research, 2020, 26, 170-179.	0.6	2
131	Longitudinal expression changes are weak correlates of disease progression in Huntington's disease. Brain Communications, 2020, 2, fcaa172.	3.3	6
132	Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. Lancet Neurology, The, 2019, 18, 942-952.	10.2	178
133	Tackling gaps in developing lifeâ€changing treatments for dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 241-253.	3.7	17
134	Amyloid precursor protein processing in human neurons with an allelic series of the PSEN1 intron 4 deletion mutation and total presenilin-1 knockout. Brain Communications, 2019, 1, fcz024.	3.3	13
135	Hippocampal subfield volumes and pre-clinical Alzheimer's disease in 408 cognitively normal adults born in 1946. PLoS ONE, 2019, 14, e0224030.	2.5	26
136	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. Lancet Neurology, The, 2019, 18, 1103-1111.	10.2	128
137	Cognition at age 70. Neurology, 2019, 93, e2144-e2156.	1.1	37
138	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	4.2	33
139	SILK studies — capturing the turnover of proteins linked to neurodegenerative diseases. Nature Reviews Neurology, 2019, 15, 419-427.	10.1	37
140	MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1. Brain, 2019, 142, 1876-1886.	7.6	114
141	Longitudinal neuroanatomical and cognitive progression of posterior cortical atrophy. Brain, 2019, 142, 2082-2095.	7.6	64
142	Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease. Brain, 2019, 142, 1429-1440.	7.6	36
143	Polygenic risk and hazard scores for Alzheimer's disease prediction. Annals of Clinical and Translational Neurology, 2019, 6, 456-465.	3.7	70
144	Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: a GENFI study. Brain, 2019, 142, 1108-1120.	7.6	41

#		Article	IF	CITATIONS
14	5	Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 740-746.	1.9	23
14	6	ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloidâ€∔² copathology. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 277-280.	2.4	24
14	7	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 19.	6.2	65
14	8	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
14	9	O3â€03â€01: THE SEQUENCE AND TIMING OF PRECLINICAL COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P882.	0.8	1
15	0	ICâ€Pâ€007: CENTILOID SCALE TRANSFORMATION OF FLORBETAPIR DATA ACQUIRED ON A PET/MR SCANNER. Alzheimer's and Dementia, 2019, 15, P17.	0.8	0
15	1	CSF synaptic protein concentrations are raised in those with atypical Alzheimer's disease but not frontotemporal dementia. Alzheimer's Research and Therapy, 2019, 11, 105.	6.2	31
15	2	O4â€13â€01: EARLY ADULTHOOD VASCULAR RISK STRONGLY PREDICTS BRAIN VOLUMES AND WHITE MATTER DISEASE, BUT NOT AMYLOID STATUS, AT AGE 69–71 YEARS: EVIDENCE FROM A BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2019, 15, P1269.	0.8	0
15	3	Incidental findings on brain imaging and blood tests: results from the first phase of Insight 46, a prospective observational substudy of the 1946 British birth cohort. BMJ Open, 2019, 9, e029502.	1.9	16
15	4	ICâ€Pâ€006: LONGITUDINAL RATES OF AMYLOID ACCUMULATION IN A 70â€YEAR OLD BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2019, 15, P16.	0.8	0
15	5	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	2.7	27
15	6	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. JAMA Network Open, 2019, 2, e1917126.	5.9	23
15	7	Differences in hippocampal subfield volume are seen in phenotypic variants of early onset Alzheimer's disease. NeuroImage: Clinical, 2019, 21, 101632.	2.7	37
15	8	Spatiotemporal analysis for detection of pre-symptomatic shape changes in neurodegenerative diseases: Initial application to the GENFI cohort. NeuroImage, 2019, 188, 282-290.	4.2	16
15	9	Unsuccessful trials of therapies for Alzheimer's disease. Lancet, The, 2019, 393, 29.	13.7	31
16	0	Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 543-555.	1.9	87
16	1	Seizures as an early symptom of autosomal dominant Alzheimer's disease. Neurobiology of Aging, 2019, 76, 18-23.	3.1	27
16	2	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	3.1	47

#	Article	IF	CITATIONS
163	Aphasic Binary Reversals in Patients With Neurological Disease as a Barrier to Clinical Decision Making. JAMA Neurology, 2019, 76, 234.	9.0	4
164	TADPOLE Challenge: Accurate Alzheimer's Disease Prediction Through Crowdsourced Forecasting of Future Data. Lecture Notes in Computer Science, 2019, 11843, 1-10.	1.3	32
165	Title is missing!. , 2019, 14, e0224030.		0
166	Title is missing!. , 2019, 14, e0224030.		0
167	Title is missing!. , 2019, 14, e0224030.		0
168	Title is missing!. , 2019, 14, e0224030.		0
169	Cortical microstructure in young onset Alzheimer's disease using neurite orientation dispersion and density imaging. Human Brain Mapping, 2018, 39, 3005-3017.	3.6	87
170	Primary progressive aphasia: a clinical approach. Journal of Neurology, 2018, 265, 1474-1490.	3.6	185
171	Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurology, The, 2018, 17, 241-250.	10.2	383
172	Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology, 2018, 90, e877-e886.	1.1	28
173	Plasma tau is increased in frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 804-807.	1.9	41
174	Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2018, 17, 123-132.	10.2	84
175	CSF neurogranin or tau distinguish typical and atypical Alzheimer disease. Annals of Clinical and Translational Neurology, 2018, 5, 162-171.	3.7	30
176	Data-driven models of dominantly-inherited Alzheimer's disease progression. Brain, 2018, 141, 1529-1544.	7.6	111
177	Presymptomatic atrophy in autosomal dominant Alzheimer's disease: AÂserial magnetic resonance imaging study. Alzheimer's and Dementia, 2018, 14, 43-53.	0.8	42
178	Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study. Neurobiology of Aging, 2018, 62, 191-196.	3.1	151
179	Progranulin plasma levels predict the presence of GRN mutations in asymptomatic subjects and do not correlate with brain atrophy: results from the GENFI study. Neurobiology of Aging, 2018, 62, 245.e9-245.e12.	3.1	40
180	P2â€438: ROBUST IDENTIFICATION OF BRAIN STRUCTURES MOST DISCRIMINATIVE IN DETECTING EARLY CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P882.	0.8	0

#	Article	IF	CITATIONS
181	O2â€04â€03: WHAT GOES UP MUST COME DOWN: LONGITUDINAL DECLINE IN CEREBROSPINAL FLUID TAU PEPTIDES IS ASSOCIATED WITH PROGRESSIVE CORTICAL ATROPHY. Alzheimer's and Dementia, 2018, 14, P622.	0.8	0
182	P1â€188: MODELLING AMYLOID BETA PROFILES IN IPSCâ€DERIVED CORTICAL NEURONS OF MULTIPLE FAMILIAL ALZHEIMER'S DISEASE GENOTYPES, INCLUDING A CASE STUDY OF SAME DONOR CULTURE MEDIA, CSF AND BRAIN TISSUE. Alzheimer's and Dementia, 2018, 14, P350.	0.8	0
183	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.8	0
184	P2â€390: DIFFERENTIAL HIPPOCAMPAL SUBFIELD LOSS IN DIFFERENT PHENOTYPES OF YOUNG ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P850.	0.8	1
185	P4â€094: OCCIPITAL TO GLOBAL PIB UPTAKE IS ASSOCIATED WITH THE PRESENCE OF MICROHEMORRHAGES AND MUTATIONS ASSOCIATED WITH CEREBRAL AMYLOID ANGIOPATHY IN THE DOMINANTLY INHERITED ALZHEIMER'S NETWORK. Alzheimer's and Dementia, 2018, 14, P1472.	0.8	1
186	P3â€437: LONGITUDINAL CORTICAL THICKNESS IN SPORADIC YOUNG ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1281.	0.8	0
187	ICâ€Pâ€048: SAMPLE SIZE ESTIMATES FOR SECONDARY PREVENTION STUDIES USING REGIONAL ATROPHY RATE: Alzheimer's and Dementia, 2018, 14, P47.	5 _{0.8}	0
188	P1â€524: VISUAL SHORTâ€TERM BINDING DEFICIT IN FAMILIAL ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P532.	0.8	1
189	P1â€474: SURFACEâ€BASED ANALYSIS OF CORTICAL GREY MATTER MICROSTRUCTURE IN YOUNGâ€ONSET ALZHEIMER'S DISEASE USING NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING (NODDI). Alzheimer's and Dementia, 2018, 14, P505.	0.8	0
190	Using a birth cohort to study brain health and preclinical dementia: recruitment and participation rates in Insight 46. BMC Research Notes, 2018, 11, 885.	1.4	37
191	ICâ€₽â€165: ROBUST IDENTIFICATION OF BRAIN STRUCTURES MOST DISCRIMINATIVE IN DETECTING EARLY CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P138.	0.8	0
192	O2â€05â€01: INFLUENCES OF BLOOD PRESSURE AND BLOOD PRESSURE TRAJECTORIES ON CEREBRAL PATHOLC AT AGE 70: RESULTS FROM A BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2018, 14, P626.) <u>Сү</u> 0.8	1
193	P1â€410: SAMPLE SIZE ESTIMATES FOR SECONDARY PREVENTION STUDIES USING REGIONAL ATROPHY RATES. Alzheimer's and Dementia, 2018, 14, P461.	0.8	0
194	P3â€261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1174.	0.8	0
195	O3â€09â€03: SERUM NEUROFILAMENT LIGHT LEVELS CORRELATE WITH SEVERITY MEASURES AND NEURODEGENERATION MARKERS IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1037.	0.8	0
196	Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2018, 10, 113.	6.2	54
197	P1â€031: HEAD INJURY WITH LOSS OF CONSCIOUSNESS AND SUBSEQUENT COGNITIVE DECLINE: FOLLOWâ€UF THE 1946 BRITISH BIRTH COHORT STUDY. Alzheimer's and Dementia, 2018, 14, P278.	0.8	1
198	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39

#	Article	IF	CITATIONS
199	Prevalence of amyloidâ€ î ² pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132
200	White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease. Brain, 2018, 141, 3065-3080.	7.6	116
201	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. Alzheimer's Research and Therapy, 2018, 10, 112.	6.2	46
202	Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. Nature Communications, 2018, 9, 4273.	12.8	263
203	Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology, 2018, 91, e1295-e1306.	1.1	193
204	Registration-based methods applied to serial high-resolution T1-weighted magnetic resonance imaging for the assessment of brain volume changes in anorexia nervosa of the restricting type. Psychiatry Research - Neuroimaging, 2018, 279, 14-18.	1.8	1
205	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
206	Long-Term Follow Up of Patients with Mild-to-Moderate Alzheimer's Disease Treated with Bapineuzumab in a Phase III, Open-Label, Extension Study. Journal of Alzheimer's Disease, 2018, 64, 689-707.	2.6	15
207	Presymptomatic white matter integrity loss in familial frontotemporal dementia in the <scp>GENFI</scp> cohort: A crossâ€sectional diffusion tensor imaging study. Annals of Clinical and Translational Neurology, 2018, 5, 1025-1036.	3.7	39
208	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's Research and Therapy, 2018, 10, 32.	6.2	79
209	Pathological correlates of white matter hyperintensities in a case of progranulin mutation associated frontotemporal dementia. Neurocase, 2018, 24, 166-174.	0.6	40
210	Cerebrospinal fluid soluble TREM2 levels in frontotemporal dementia differ by genetic and pathological subgroup. Alzheimer's Research and Therapy, 2018, 10, 79.	6.2	43
211	White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer's disease. PLoS ONE, 2018, 13, e0195838.	2.5	51
212	The clinical, neuroanatomical, and neuropathologic phenotype of <i>TBK1</i> â€associated frontotemporal dementia: A longitudinal case report. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 75-81.	2.4	28
213	Improving data availability for brain image biobanking in healthy subjects: Practice-based suggestions from an international multidisciplinary working group. NeuroImage, 2017, 153, 399-409.	4.2	13
214	APOE ε4 status is associated with white matter hyperintensities volume accumulation rate independent of AD diagnosis. Neurobiology of Aging, 2017, 53, 67-75.	3.1	44
215	Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Health, The, 2017, 2, e149-e156.	10.0	101
216	Redefining the phenotype of ALSP and <i>AARS2</i> mutation–related leukodystrophy. Neurology: Genetics, 2017, 3, e135.	1.9	64

#	Article	IF	CITATIONS
217	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.8	423
218	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 908-916.	1.9	78
219	Cognitive reserve and TMEM106B genotype modulate brain damage in presymptomatic frontotemporal dementia: a GENFI study. Brain, 2017, 140, 1784-1791.	7.6	55
220	ApoE influences regional white-matter axonal density loss in Alzheimer's disease. Neurobiology of Aging, 2017, 57, 8-17.	3.1	82
221	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
222	White matter hyperintensities are seen only in GRN mutation carriers in the GENFI cohort. NeuroImage: Clinical, 2017, 15, 171-180.	2.7	63
223	Clinical and genetic characterization of leukoencephalopathies in adults. Brain, 2017, 140, 1204-1211.	7.6	73
224	A Comparison of Accelerated and Non-accelerated MRI Scans for Brain Volume and Boundary Shift Integral Measures of Volume Change: Evidence from the ADNI Dataset. Neuroinformatics, 2017, 15, 215-226.	2.8	14
225	White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy. Hippocampus, 2017, 27, 249-262.	1.9	62
226	Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89, 2167-2175.	1.1	204
227	Dementia prevention, intervention, and care. Lancet, The, 2017, 390, 2673-2734.	13.7	4,228
228	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
229	Alzheimer's-Causing Mutations Shift Aβ Length by Destabilizing γ-Secretase-Aβn Interactions. Cell, 2017, 170, 443-456.e14.	28.9	199
230	The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial. Journal of Alzheimer's Disease, 2017, 61, 803-814.	2.6	28
231	[ICâ€₽â€004]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MI SCANNER. Alzheimer's and Dementia, 2017, 13, P12.	² 0.8	0
232	Inhibiting the Ca 2+ Influx Induced by Human CSF. Cell Reports, 2017, 21, 3310-3316.	6.4	20
233	[P2–441]: PATHOLOGICAL CORRELATES OF WHITE MATTER HYPERINTENSITIES ON CADAVERIC MRI IN PROGRANULINâ€ASSOCIATED FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P805.	0.8	0
234	Amyloid polymorphisms constitute distinct clouds of conformational variants in different etiological subtypes of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 13018-13023.	7.1	170

NICK C FOX

#	Article	IF	CITATIONS
235	[P4–261]: LONGITUDINAL EVALUATION OF NEUROPSYCHOLOGICAL AND NEUROIMAGING PROGRESSION IN POSTERIOR CORTICAL ATROPHY. Alzheimer's and Dementia, 2017, 13, P1382.	0.8	0
236	[P1–443]: MULTIPLE DISTINCT ATROPHY PATTERNS FOUND IN GENETIC FRONTOTEMPORAL DEMENTIA USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). Alzheimer's and Dementia, 2017, 13, P453.	0.8	1
237	[ICâ€Pâ€079]: MULTIPLE DISTINCT ATROPHY PATTERNS FOUND IN GENETIC FRONTOTEMPORAL DEMENTIA USIN SUBTYPE AND STAGE INFERENCE (SUSTAIN). Alzheimer's and Dementia, 2017, 13, P65.	С 0.8	0
238	Study protocol: Insight 46 – a neuroscience sub-study of the MRC National Survey of Health and Development. BMC Neurology, 2017, 17, 75.	1.8	64
239	Effect of Spinal Manometers on Cerebrospinal Fluid Amyloid-β Concentration. Journal of Alzheimer's Disease, 2017, 56, 885-891.	2.6	6
240	BRain health and healthy AgeINg in retired rugby union players, the BRAIN Study: study protocol for an observational study in the UK. BMJ Open, 2017, 7, e017990.	1.9	9
241	[P1–219]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2 AND 3D. Alzheimer's and Dementia, 2017, 13, P327.	D _{0.8}	0
242	[P1–220]: 3D CEREBRAL ORGANOIDS AS IN VITRO MODELS FOR ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P327.	0.8	0
243	[P1–025]: PROBING DEVELOPMENTAL CONSEQUENCES OF PSEN1 MUTATIONS IN IPSC DIFFERENTIATION IN 2 AND 3D. Alzheimer's and Dementia, 2017, 13, P242.	D _{0.8}	0
244	[P2–414]: CHARACTERISING THE PROGRESSION OF ALZHEIMER's DISEASE SUBTYPES USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). Alzheimer's and Dementia, 2017, 13, P791.	0.8	0
245	[P2–458]: VISUOMOTOR INTEGRATION IN PRESYMPTOMATIC FAMILIAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P815.	0.8	1
246	[P2–545]: VASCULAR AND EARLY LIFE INFLUENCES ON CEREBROVASCULAR DISEASE IN INSIGHT 46: A SUBâ€STUDY OF THE MRC NATIONAL SURVEY OF HEALTH AND DEVELOPMENT (NSHD) BRITISH BIRTH COHORT. Alzheimer's and Dementia, 2017, 13, P851.	0.8	0
247	[P3–327]: THE ADNI3 DIFFUSION MRI PROTOCOL: BASIC + ADVANCED. Alzheimer's and Dementia, 2017, 13, P1075.	0.8	0
248	[P3–348]: EXPLORING THE POPULATION PREVALENCE OF βâ€AMYLOID BURDEN: AN ANALYSIS OF 250 INDIVIDUALS BORN IN MAINLAND BRITAIN IN THE SAME WEEK IN 1946. Alzheimer's and Dementia, 2017, 13, P1088.	0.8	0
249	[P3–373]: A COMPARISON OF TECHNIQUES FOR QUANTIFYING AMYLOID BURDEN ON A COMBINED PET/MR SCANNER. Alzheimer's and Dementia, 2017, 13, P1100.	0.8	0
250	[P4–230]: LONGITUDINAL NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING IN YOUNGâ€ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1359.	0.8	0
251	[P4–257]: ANALYSIS OF THE HETEROGENEITY OF POSTERIOR CORTICAL ATROPHY: DATAâ€DRIVEN MODEL PREDICTS DISTINCT ATROPHY PATTERNS FOR THREE DIFFERENT COGNITIVE SUBGROUPS. Alzheimer's and Dementia, 2017, 13, P1379.	0.8	0
252	[P4–289]: CAN EYETRACKING METRICS RELATE TO PERFORMANCE ON VISUAL COGNITIVE TESTS OF INDIVIDUALS WITH YOUNGâ€ONSET ALZHEIMER'S DISEASE?. Alzheimer's and Dementia, 2017, 13, P1397.	0.8	0

#	Article	IF	CITATIONS
253	[ICâ€Pâ€137]: ADNIâ€3 MRI PROTOCOL. Alzheimer's and Dementia, 2017, 13, P104.	0.8	8
254	[ICâ€Pâ€141]: ANALYSIS OF THE HETEROGENEITY OF POSTERIOR CORTICAL ATROPHY: DATAâ€DRIVEN MODEL PREDICTS DISTINCT ATROPHY PATTERNS FOR THREE DIFFERENT COGNITIVE SUBGROUPS. Alzheimer's and Dementia, 2017, 13, P106.	0.8	0
255	[ICâ€Pâ€150]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P113.	0.8	0
256	[P1–180]: DISTINCT Aβ PRODUCTION IN STEM CELLâ€ÐERIVED CORTICAL NEURONS FROM PATIENTS WITH F⁄ MUTATION. Alzheimer's and Dementia, 2017, 13, P311.	AD 0.8	0
257	[ICâ€Pâ€154]: CHARACTERISING THE PROGRESSION OF ALZHEIMER's DISEASE SUBTYPES USING SUBTYPE AND STAGE INFERENCE (SUSTAIN). Alzheimer's and Dementia, 2017, 13, P116.	0.8	2
258	[ICâ€Pâ€168]: LONGITUDINAL NEURITE ORIENTATION DISPERSION AND DENSITY IMAGING IN YOUNGâ€ONSET ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P127.	0.8	0
259	[P1–335]: THEMES AND VARIATIONS IN PPA: A CLINICAL AND NEUROBIOLOGICAL ANALYSIS OF THE UCL COHORT. Alzheimer's and Dementia, 2017, 13, P384.	0.8	0
260	[P2–241]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P703.	0.8	0
261	[O1–02–02]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P185.	0.8	0
262	[F4–01–04]: NEUROIMAGING AND HETEROGENEITY IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1211.	0.8	0
263	[O4–02–04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.8	0
264	[O5–05–04]: BRAIN VOLUME, CEREBRAL βâ€AMYLOID DEPOSITION, AND AGEING: A STUDY OF OVER 200 INDIVIDUALS BORN IN THE SAME WEEK IN 1946. Alzheimer's and Dementia, 2017, 13, P1464.	0.8	0
265	Eyetracking Metrics in Young Onset Alzheimer's Disease: A Window into Cognitive Visual Functions. Frontiers in Neurology, 2017, 8, 377.	2.4	50
266	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. Alzheimer's Research and Therapy, 2017, 9, 85.	6.2	52
267	Preparatory planning framework for Created Out of Mind: Shaping perceptions of dementia through art and science. Wellcome Open Research, 2017, 2, 108.	1.8	18
268	DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER'S DISEASE. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-7.	2.7	65
269	EU/US/CTAD TASK FORCE: LESSONS LEARNED FROM RECENT AND CURRENT ALZHEIMER'S PREVENTION TRIALS. journal of prevention of Alzheimer's disease, The, 2017, 4, 1-9.	2.7	18
270	Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 49, 1123-1134.	2.6	38

#	Article	IF	CITATIONS
271	Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group. PLoS ONE, 2016, 11, e0152082.	2.5	45
272	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. Journal of Alzheimer's Disease, 2016, 54, 1297-1302.	2.6	21
273	Two Phase 2 Multiple Ascending–Dose Studies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 1131-1143.	2.6	78
274	P1â€025: Cerebral Perfusion as an Imaging Biomarker of Presymptomatic Genetic Frontotemporal Dementia: Preliminary Results from the Genetic Frontotemporal Dementia Initiative (GENFI). Alzheimer's and Dementia, 2016, 12, P409.	0.8	0
275	P2â€015: Pooled Amyloid Pet Baseline Data from The Bapineuzumab IV Phase III Trials. Alzheimer's and Dementia, 2016, 12, P614.	0.8	0
276	ICâ€Pâ€142: A Longitudinal Morphometric Study of Familial Alzheimer's Disease: Results from Dian. Alzheimer's and Dementia, 2016, 12, P105.	0.8	0
277	ICâ€Pâ€161: Phenotypic Differences in Quantitative MRI Parameters in Typical Amnestic Alzheimer's Disease and PCA in a Youngâ€Onset Alzheimer's Cohort. Alzheimer's and Dementia, 2016, 12, P119.	0.8	1
278	FTS3â€01â€03: Biomarkers for Vascular Contributions to Dementia. Alzheimer's and Dementia, 2016, 12, P276.	0.8	0
279	O1â€07â€01: A Longitudinal Morphometric Study of Familial Alzheimer's Disease: Results From DIAN. Alzheimer's and Dementia, 2016, 12, P187.	0.8	0
280	O1â€11â€05: CSF In the Differential Diagnosis of Alzheimer's Disease: Clinical Utility of an Extended Panel Of Biomarkers in a Specialist Cognitive Clinic. Alzheimer's and Dementia, 2016, 12, P203.	0.8	1
281	O2-04-05: Accelerated Long-Term Forgetting in Presymptomatic Familial Alzheimer's Disease. , 2016, 12, P231-P231.		2
282	F5â€02â€02: Longitudinal Atrophy in Autosomal Dominant Ad and Sporadic Ad: Lessons from Dian. Alzheimer's and Dementia, 2016, 12, P368.	0.8	0
283	O5-02-01: Longitudinal Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease: The Dominantly Inherited Alzheimer Network. , 2016, 12, P378-P379.		0
284	P1â€009: A Dataâ€Driven Comparison of the Progression of Brain Atrophy in Posterior Cortical Atrophy and Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P401.	0.8	1
285	P1â€204: Neurogranin: a Specific Synaptic Biomarker for Amnestic Alzheimer's Disease?. Alzheimer's and Dementia, 2016, 12, P483.	0.8	0
286	Genetic risk factors for the posterior cortical atrophy variant of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 862-871.	0.8	93
287	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. Neurobiology of Aging, 2016, 39, 99-107.	3.1	34
288	Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine. JAMA Neurology, 2016, 73, 1454.	9.0	25

#	Article	IF	CITATIONS
289	Hyperphosphorylated tau in patients with refractory epilepsy correlates with cognitive decline: a study of temporal lobe resections. Brain, 2016, 139, 2441-2455.	7.6	193
290	Advances in neuroimaging in frontotemporal dementia. Journal of Neurochemistry, 2016, 138, 193-210.	3.9	75
291	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
292	Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology, 2016, 87, 1329-1336.	1.1	354
293	Presymptomatic cortical thinning in familial Alzheimer disease. Neurology, 2016, 87, 2050-2057.	1.1	58
294	Analysis of Mutations in <i>AARS2</i> in a Series of <i>CSF1R</i> -Negative Patients With Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia. JAMA Neurology, 2016, 73, 1433.	9.0	71
295	A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. Translational Psychiatry, 2016, 6, e952-e952.	4.8	46
296	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. Lancet Neurology, The, 2016, 15, 1326-1335.	10.2	163
297	Neurological manifestations of autosomal dominant familial Alzheimer's disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS). Lancet Neurology, The, 2016, 15, 1317-1325.	10.2	87
298	A novel use of arterial spin labelling MRI to demonstrate focal hypoperfusion in individuals with posterior cortical atrophy: a multimodal imaging study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1032-1034.	1.9	9
299	Effect of age at onset on cortical thickness and cognition in posterior cortical atrophy. Neurobiology of Aging, 2016, 44, 108-113.	3.1	11
300	White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network. Annals of Neurology, 2016, 79, 929-939.	5.3	381
301	Increased CSF neurogranin concentration is specific to Alzheimer disease. Neurology, 2016, 86, 829-835.	1.1	170
302	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. Brain, 2016, 139, 1211-1225.	7.6	174
303	Characterization of tau positron emission tomography tracer [¹⁸ F]AVâ€1451 binding to postmortem tissue in Alzheimer's disease,Âprimary tauopathies, and other dementias. Alzheimer's and Dementia, 2016, 12, 1116-1124.	0.8	161
304	Visual short-term memory binding deficit in familial Alzheimer's disease. Cortex, 2016, 78, 150-164.	2.4	77
305	Inflammatory changes in very early Alzheimer's disease: friend, foe, or don't know?. Brain, 2016, 139, 647-650.	7.6	4
306	Stem cell therapy for Alzheimer's disease: hope or hype?. Lancet Neurology, The, 2016, 15, 133-135.	10.2	16

#	Article	IF	CITATIONS
307	Why has therapy development for dementia failed in the last two decades?. Alzheimer's and Dementia, 2016, 12, 60-64.	0.8	194
308	<i>CHCHD10</i> Pro34Ser is not a highly penetrant pathogenic variant for amyotrophic lateral sclerosis and frontotemporal dementia. Brain, 2016, 139, e9-e9.	7.6	7
309	A novel Alzheimer disease locus located near the gene encoding tau protein. Molecular Psychiatry, 2016, 21, 108-117.	7.9	260
310	Hereditary leukoencephalopathy with axonal spheroids: a spectrum of phenotypes from CNS vasculitis to parkinsonism in an adult onset leukodystrophy series. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 512-519.	1.9	58
311	IC-P-106: Reproducibility of hippocampal atrophy rate at 1.5T and 3T for freesurfer and MAPS-HBSI using the ADNI1 data set. , 2015, 11, P72-P73.		0
312	IC-P-117: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes. , 2015, 11, P80-P81.		0
313	F1-04-04: The search for effective therapies for ad and related disorders must not be abandoned, and biomarkers will be important in that search. , 2015, 11, P120-P120.		0
314	O1-02-06: Neurite orientation dispersion and density imaging (NODDI) in young onset Alzheimer's disease and its syndromic variants. , 2015, 11, P128-P129.		0
315	IC-P-134: Neurite orientation dispersion and density imaging (NODDI) in young-onset Alzheimer's disease and its syndromic variants. , 2015, 11, P91-P91.		1
316	P1-191: Using florbetapir F18 PET to validate CSF cut-points and increase diagnostic certainty in atypical dementias. , 2015, 11, P421-P422.		0
317	P1-211: Genetic influences on amyloid angiopathy and white matter pathology in familial Alzheimer's disease: A comparison of app and PSEN1 mutations. , 2015, 11, P431-P431.		0
318	P2-120: Dementia and music: fMRI signatures of molecular nexopathies. , 2015, 11, P528-P528.		0
319	P3-075: Development of a targeted proteomic multiplex CSF assay for neurodegenerative markers. , 2015, 11, P645-P646.		0
320	IC-P-133: Music as a probe of default mode network function in young-onset Alzheimer's disease. , 2015, 11, P91-P91.		0
321	P2-153: Music as a probe of default mode network function in young onset Alzheimer's disease. , 2015, 11, P545-P546.		0
322	Longitudinal diffusion tensor imaging in frontotemporal dementia. Annals of Neurology, 2015, 77, 33-46.	5.3	82
323	Differential hippocampal shapes in posterior cortical atrophy patients: A comparison with control and typical <scp>AD</scp> subjects. Human Brain Mapping, 2015, 36, 5123-5136.	3.6	19
324	A Novel MAPT Mutation Causing Corticobasal Syndrome Led by Progressive Apraxia of Speech. Journal of Alzheimer's Disease, 2015, 48, 923-926.	2.6	16

#	Article	IF	CITATIONS
325	Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 380-384.	2.4	5
326	IC-P-092: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P64-P64.		0
327	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 440-446.	2.4	16
328	O3-14-01: Dissecting IWG-2 typical and atypical Alzheimer's disease: Insights from cerebrospinal fluid analysis. , 2015, 11, P254-P254.		0
329	Diffusion imaging changes in grey matter in Alzheimer's disease: a potential marker of early neurodegeneration. Alzheimer's Research and Therapy, 2015, 7, 47.	6.2	132
330	Reversible frontotemporal brain sagging syndrome. Neurology, 2015, 85, 833-833.	1.1	6
331	Developmental regulation of tau splicing is disrupted in stem cell-derived neurons from frontotemporal dementia patients with the 10 + 16 splice-site mutation in MAPT. Human Molecular Genetics, 2015, 24, 5260-5269.	2.9	116
332	Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Molecular Neurodegeneration, 2015, 10, 64.	10.8	121
333	P1-100: A cross-sectional and longitudinal investigation of the cambridge behavioral inventory-revised (CBI-R) in behavioral variant frontotemporal dementia. , 2015, 11, P377-P377.		0
334	O2-01-06: Measurement of cortical mean diffusivity detects early microstructural breakdown of the cerebral cortex in presymptomatic familial Alzheimer's disease. , 2015, 11, P174-P174.		0
335	IC-P-093: Distinct patterns of atrophy in postmortem confirmed dementias. , 2015, 11, P64-P65.		0
336	P3-170: Reproducibility of hippocampal atrophy rate at 1.5T and 3T for freesurfer and MAPS-HBSI using the ADNI1 data set. , 2015, 11, P694-P695.		0
337	P3-204: The neurolinguistic profile of behavioral variant frontotemporal dementia. , 2015, 11, P710-P711.		0
338	P1-010: Quantification of the synaptic protein neurogranin in cerebrospinal fluid across different neurodegenerative diseases: A selective Alzheimer's disease biomarker?. , 2015, 11, P340-P340.		0
339	P3-060: Effects of age at onset on cognition and cortical thickness in posterior cortical atrophy. , 2015, 11, P640-P641.		0
340	F2-03-04: Genetic risk factors for posterior cortical atrophy. , 2015, 11, P168-P169.		2
341	O2-01-05: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes. , 2015, 11, P173-P174.		0
342	O4-08-05: Distinct patterns of atrophy in postmortem-confirmed dementias. , 2015, 11, P288-P289.		0

#	Article	IF	CITATIONS
343	O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P289-P289.		0
344	Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional analysis. Lancet Neurology, The, 2015, 14, 253-262.	10.2	432
345	Spontaneous ARIA (Amyloid-Related Imaging Abnormalities) and Cerebral Amyloid Angiopathy Related Inflammation in Presenilin 1-Associated Familial Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1069-1074.	2.6	22
346	Brain Amyloid-Beta Fragment Signatures in Pathological Ageing and Alzheimer's Disease by Hybrid Immunoprecipitation Mass Spectrometry. Neurodegenerative Diseases, 2015, 15, 50-57.	1.4	41
347	A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1240-1247.	1.9	196
348	White matter tract signatures of impaired social cognition in frontotemporal lobar degeneration. NeuroImage: Clinical, 2015, 8, 640-651.	2.7	65
349	Accurate automatic estimation of total intracranial volume: A nuisance variable with less nuisance. NeuroImage, 2015, 104, 366-372.	4.2	371
350	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. Alzheimer's and Dementia, 2015, 11, 740-756.	0.8	142
351	Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 1225-1233.	1.9	114
352	Accelerated vs. unaccelerated serial MRI based TBM-SyN measurements for clinical trials in Alzheimer's disease. NeuroImage, 2015, 113, 61-69.	4.2	38
353	Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis. Journal of Neurology, 2015, 262, 2722-2730.	3.6	39
354	Genetic determinants of white matter hyperintensities and amyloid angiopathy in familial Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3140-3151.	3.1	53
355	Qualitative changes in human γ-secretase underlie familial Alzheimer's disease. Journal of Experimental Medicine, 2015, 212, 2003-2013.	8.5	134
356	Alzheimer's disease in the 100 years since Alzheimer's death. Brain, 2015, 138, 3816-3821.	7.6	50
357	The importance of dementia support groups. BMJ, The, 2015, 351, h3875.	6.0	3
358	Amyloid-β ¹¹ C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials. Neurology, 2015, 85, 692-700.	1.1	136
359	Assessing atrophy measurement techniques in dementia: Results from the MIRIAD atrophy challenge. NeuroImage, 2015, 123, 149-164.	4.2	63
360	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173

#	Article	IF	CITATIONS
361	Effects of changing from non-accelerated to accelerated MRI for follow-up in brain atrophy measurement. NeuroImage, 2015, 107, 46-53.	4.2	20
362	Measuring brain atrophy with a generalized formulation of the boundary shift integral. Neurobiology of Aging, 2015, 36, S81-S90.	3.1	24
363	Multiple Orderings of Events in Disease Progression. Lecture Notes in Computer Science, 2015, 24, 711-722.	1.3	22
364	APOE Îμ4 Is Associated with Disproportionate Progressive Hippocampal Atrophy in AD. PLoS ONE, 2014, 9, e97608.	2.5	53
365	A cognitive chameleon: Lessons from a novel <i>MAPT</i> mutation case. Neurocase, 2014, 20, 684-694.	0.6	12
366	ADULT LEUKODYSTROPHY: MULTI-DISCIPLINARY STRUCTURED APPROACH. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.196-e4.	1.9	1
367	Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Translational Psychiatry, 2014, 4, e419-e419.	4.8	39
368	The search for early markers of AD: hippocampal atrophy and memory deficits. International Psychogeriatrics, 2014, 26, 1065-1066.	1.0	11
369	A data-driven model of biomarker changes in sporadic Alzheimer's disease. Brain, 2014, 137, 2564-2577.	7.6	243
370	Imaging endpoints for clinical trials in Alzheimer's disease. Alzheimer's Research and Therapy, 2014, 6, 87.	6.2	47
371	Learning Imaging Biomarker Trajectories from Noisy Alzheimer's Disease Data Using a Bayesian Multilevel Model. Lecture Notes in Computer Science, 2014, , 85-94.	1.3	15
372	Simulating Neurodegeneration through Longitudinal Population Analysis of Structural and Diffusion Weighted MRI Data. Lecture Notes in Computer Science, 2014, 17, 57-64.	1.3	7
373	Functional Connectivity in Autosomal Dominant and Late-Onset Alzheimer Disease. JAMA Neurology, 2014, 71, 1111.	9.0	112
374	Automated Template-Based Hippocampal Segmentations from MRI: The Effects of 1.5T or 3T Field Strength on Accuracy. Neuroinformatics, 2014, 12, 405-412.	2.8	11
375	TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions. Acta Neuropathologica, 2014, 127, 407-418.	7.7	123
376	An algorithmic approach to structural imaging in dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 692-698.	1.9	98
377	Profiles of white matter tract pathology in frontotemporal dementia. Human Brain Mapping, 2014, 35, 4163-4179.	3.6	102
378	A practical approach to diagnosing adult onset leukodystrophies. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 770-781.	1.9	80

#	Article	IF	CITATIONS
379	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurology, The, 2014, 13, 614-629.	10.2	2,657
380	Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease. New England Journal of Medicine, 2014, 370, 322-333.	27.0	1,613
381	<i>R47H TREM2</i> variant increases risk of typical earlyâ€onset Alzheimer's disease but not of prion or frontotemporal dementia. Alzheimer's and Dementia, 2014, 10, 602.	0.8	94
382	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 421.	0.8	77
383	Biomarkers in dementia: clinical utility and new directions. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1426-1434.	1.9	119
384	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
385	Symptom onset in autosomal dominant Alzheimer disease. Neurology, 2014, 83, 253-260.	1.1	391
386	Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. Neurobiology of Aging, 2014, 35, 808-818.	3.1	37
387	Validation of next-generation sequencing technologies in genetic diagnosis of dementia. Neurobiology of Aging, 2014, 35, 261-265.	3.1	59
388	Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet, The, 2014, 383, 2213-2221.	13.7	361
389	Motor features in posterior cortical atrophy and their imaging correlates. Neurobiology of Aging, 2014, 35, 2845-2857.	3.1	29
390	The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. Alzheimer's Research and Therapy, 2014, 6, 47.	6.2	24
391	IC-P-193: AUTOMATED SEGMENTATION OF THALAMUS FROM MRI: METHOD VALIDATION AND COMPARISON FOR VOLUMETRIC MEASUREMENT IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P107-P108.		0
392	P2-199: DIFFERENT PATTERNS OF STRUCTURAL CONNECTIVITY IN EARLY-ONSET SPORADIC AD: A LONGITUDINAL DTI STUDY OF WHITE MATTER STRUCTURE IN PCA AND TYPICAL AD. , 2014, 10, P544-P545.		0
393	P4-121: AGE AND WMH HAVE INDEPENDENT ASSOCIATIONS WITH WHOLE BRAIN AND HIPPOCAMPAL ATROPHY RATES. , 2014, 10, P828-P829.		0
394	P1-235: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS. , 2014, 10, P390-P391.		0
395	P1-256: A CORTICAL ATROPHY SIGNATURE OF FAMILIAL ALZHEIMER'S DISEASE: TEMPORAL EVOLUTION OF PRESYMPTOMATIC CHANGES. , 2014, 10, P401-P401.		0
396	IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS., 2014, 10, P32-P33.		0

#	Article	IF	CITATIONS
397	IC-P-126: WHITE MATTER HYPERINTENSITY VOLUME IS ASSOCIATED WITH DISPROPORTIONATE PROGRESSIVE HIPPOCAMPAL ATROPHY IN CONTROLS. , 2014, 10, P71-P73.		0
398	IC-P-224: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS. , 2014, 10, P120-P121.		0
399	IC-P-082: MULTI-MODAL IMAGE REGISTRATION: APPLICATION TO FAMILIAL AD SUBJECTS. , 2014, 10, P46-P47.		0
400	IC-P-175: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P97-P98.		0
401	P1-286: STRATIFICATION OF DEMENTIA SUB-TYPES USING ARTERIAL SPIN LABELED MRI. , 2014, 10, P414-P415.		1
402	IC-P-127: AGE AND WMH HAVE INDEPENDENT ASSOCIATIONS WITH WHOLE BRAIN AND HIPPOCAMPAL ATROPHY RATES. , 2014, 10, P73-P74.		0
403	P4-127: WHITE MATTER HYPERINTENSITY VOLUME IS ASSOCIATED WITH DISPROPORTIONATE PROGRESSIVE HIPPOCAMPAL ATROPHY IN CONTROLS. , 2014, 10, P831-P833.		0
404	P4-133: MULTI-MODAL IMAGE REGISTRATION: APPLICATION TO FAMILIAL AD SUBJECTS. , 2014, 10, P835-P836.		0
405	IC-P-125: DIFFERENTIAL HIPPOCAMPAL SHAPES IN POSTERIOR CORTICAL ATROPHY PATIENTS: A COMPARISON WITH CONTROL AND TYPICAL AD SUBJECTS. , 2014, 10, P71-P71.		0
406	O1-07-02: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P141-P142.		0
407	IC-P-106: LONGITUDINAL RATES OF ATROPHY IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P59-P60.		0
408	IC-P-112: DIFFERENT PATTERNS OF STRUCTURAL CONNECTIVITY IN EARLY-ONSET SPORADIC AD: A LONGITUDINAL DTI STUDY OF WHITE MATTER STRUCTURE IN PCA AND TYPICAL AD. , 2014, 10, P62-P63.		0
409	P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS. , 2014, 10, P540-P541.		0
410	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
411	STEPS: Similarity and Truth Estimation for Propagated Segmentations and its application to hippocampal segmentation and brain parcelation. Medical Image Analysis, 2013, 17, 671-684.	11.6	215
412	Molecular nexopathies: a new paradigm of neurodegenerative disease. Trends in Neurosciences, 2013, 36, 561-569.	8.6	223
413	Large C9orf72 Hexanucleotide Repeat Expansions Are Seen in Multiple Neurodegenerative Syndromes and Are More Frequent Than Expected in the UK Population. American Journal of Human Genetics, 2013, 92, 345-353.	6.2	297
414	White matter tract signatures of the progressive aphasias. Neurobiology of Aging, 2013, 34, 1687-1699.	3.1	97

#	Article	IF	CITATIONS
415	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
416	Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease. Proceedings of the United States of America, 2013, 110, E4502-9.	7.1	309
417	Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurology, The, 2013, 12, 822-838.	10.2	3,919
418	The midbrain to pons ratio. Neurology, 2013, 80, 1856-1861.	1.1	153
419	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. Neurobiology of Aging, 2013, 34, 73-82.	3.1	41
420	A novel A781V mutation in the CSF1R gene causes hereditary diffuse leucoencephalopathy with axonal spheroids. Journal of the Neurological Sciences, 2013, 332, 141-144.	0.6	18
421	The G8 Dementia Research Summit—a starter for eight?. Lancet, The, 2013, 382, 1968-1969.	13.7	36
422	Patterns of longitudinal brain atrophy in the logopenic variant of primary progressive aphasia. Brain and Language, 2013, 127, 121-126.	1.6	116
423	An unbiased longitudinal analysis framework for tracking white matter changes using diffusion tensor imaging with application to Alzheimer's disease. NeuroImage, 2013, 72, 153-163.	4.2	111
424	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
425	Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Revue Neurologique, 2013, 169, 737-743.	1.5	122
426	Imaging markers for Alzheimer disease. Neurology, 2013, 81, 487-500.	1.1	204
427	Standardization of analysis sets for reporting results from ADNI MRI data. Alzheimer's and Dementia, 2013, 9, 332-337.	0.8	172
428	Presymptomatic studies in genetic frontotemporal dementia. Revue Neurologique, 2013, 169, 820-824.	1.5	44
429	IC-O1-02: Are early atrophy patterns in autosomal dominant familial Alzheimer's disease gene-dependent?. , 2013, 9, P3-P4.		0
430	MIRIAD—Public release of a multiple time point Alzheimer's MR imaging dataset. NeuroImage, 2013, 70, 33-36.	4.2	111
431	Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls. Neurobiology of Aging, 2013, 34, 1996-2002.	3.1	66
432	Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurology, The, 2013, 12, 637-649.	10.2	704

#	Article	IF	CITATIONS
433	Pathogenic VCP Mutations Induce Mitochondrial Uncoupling and Reduced ATP Levels. Neuron, 2013, 78, 57-64.	8.1	127
434	Genetic Analysis of Inherited Leukodystrophies. JAMA Neurology, 2013, 70, 875.	9.0	147
435	Reply: Implications of presymptomatic change in thalamus and caudate in Alzheimer's disease. Brain, 2013, 136, e259-e259.	7.6	3
436	The pattern of atrophy in familial Alzheimer disease. Neurology, 2013, 81, 1425-1433.	1.1	67
437	Cerebral atrophy in mild cognitive impairment and Alzheimer disease. Neurology, 2013, 80, 648-654.	1.1	133
438	Exome sequencing reveals a novel partial deletion in the progranulin gene causing primary progressive aphasia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1411-1412.	1.9	9
439	Impaired default network functional connectivity in autosomal dominant Alzheimer disease. Neurology, 2013, 81, 736-744.	1.1	174
440	A Peek Behind the Curtain. Alzheimer Disease and Associated Disorders, 2013, 27, 1-3.	1.3	3
441	Identification of an important potential confound in CSF AD studies: aliquot volume. Clinical Chemistry and Laboratory Medicine, 2013, 51, 2311-7.	2.3	37
442	Magnetic resonance imaging evidence for presymptomatic change in thalamus and caudate in familial Alzheimer's disease. Brain, 2013, 136, 1399-1414.	7.6	174
443	Genetic Influences on Atrophy Patterns in Familial Alzheimer's Disease: A Comparison of APP and PSEN1 Mutations. Journal of Alzheimer's Disease, 2013, 35, 199-212.	2.6	36
444	Targeted Recruitment Using Cerebrospinal Fluid Biomarkers: Implications for Alzheimer's Disease Therapeutic Trials. Journal of Alzheimer's Disease, 2013, 34, 431-437.	2.6	7
445	Atrophy Rates in Asymptomatic Amyloidosis: Implications for Alzheimer Prevention Trials. PLoS ONE, 2013, 8, e58816.	2.5	38
446	Early-onset Alzheimer disease clinical variants. Neurology, 2012, 79, 80-84.	1.1	77
447	Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain, 2012, 135, 736-750.	7.6	392
448	Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 3985-3990.	7.1	50
449	Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a006213-a006213.	6.2	502
450	Rates of Hemispheric and Lobar Atrophy in the Language Variants of Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2012, 30, 407-411.	2.6	47

NICK C FOX

#	Article	IF	CITATIONS
451	Distinct neuropsychological profiles correspond to distribution of cortical thinning in inherited prion disease caused by insertional mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 109-114.	1.9	14
452	Cerebral microbleeds in familial Alzheimer's disease. Brain, 2012, 135, e201-e201.	7.6	15
453	The Role of Variation at AβPP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	2.6	53
454	Memantine and Brain Atrophy in Alzheimer's Disease: A 1-Year Randomized Controlled Trial. Journal of Alzheimer's Disease, 2012, 29, 459-469.	2.6	35
455	<scp>EFNS</scp> task force: the use of neuroimaging in the diagnosis of dementia. European Journal of Neurology, 2012, 19, 1487-1501.	3.3	112
456	Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease. New England Journal of Medicine, 2012, 367, 795-804.	27.0	3,005
457	Posterior cortical atrophy: advice for diagnosis and implications for management. Neurodegenerative Disease Management, 2012, 2, 599-607.	2.2	2
458	Global gray matter changes in posterior cortical atrophy: A serial imaging study. Alzheimer's and Dementia, 2012, 8, 502-512.	0.8	45
459	O2â€06â€01: Disrupted functional connectivity in autosomal dominant Alzheimer's disease: Preliminary findings from the DIAN study. Alzheimer's and Dementia, 2012, 8, P244.	0.8	1
460	Gray matter atrophy rate as a marker of disease progression in AD. Neurobiology of Aging, 2012, 33, 1194-1202.	3.1	65
461	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. Neurobiology of Aging, 2012, 33, 627.e1-627.e12.	3.1	74
462	When, where, and how does Alzheimer's disease start?. Lancet Neurology, The, 2012, 11, 1017-1018.	10.2	7
463	Consistent multi-time-point brain atrophy estimation from the boundary shift integral. NeuroImage, 2012, 59, 3995-4005.	4.2	61
464	An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease. NeuroImage, 2012, 60, 1880-1889.	4.2	192
465	Cortical Folding Analysis on Patients with Alzheimer's Disease and Mild Cognitive Impairment. Lecture Notes in Computer Science, 2012, 15, 289-296.	1.3	9
466	Geodesic Information Flows. Lecture Notes in Computer Science, 2012, 15, 262-270.	1.3	27
467	Longitudinal neuroimaging and neuropsychological profiles of frontotemporal dementia with C9ORF72 expansions. Alzheimer's Research and Therapy, 2012, 4, 41.	6.2	89
468	The Importance of Group-Wise Registration in Tract Based Spatial Statistics Study of Neurodegeneration: A Simulation Study in Alzheimer's Disease. PLoS ONE, 2012, 7, e45996.	2.5	81

#	Article	IF	CITATIONS
469	Imaging the Onset and Progression of Alzheimer's Disease: Implications for Prevention Trials. Journal of Alzheimer's Disease, 2012, 33, S305-S312.	2.6	5
470	Conventional magnetic resonance imaging in confirmed progressive supranuclear palsy and multiple system atrophy. Movement Disorders, 2012, 27, 1754-1762.	3.9	163
471	Visualizing the emergence of posterior cortical atrophy. Neurocase, 2012, 18, 248-257.	0.6	25
472	Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurology, The, 2012, 11, 42-53.	10.2	479
473	Posterior cortical atrophy. Lancet Neurology, The, 2012, 11, 170-178.	10.2	487
474	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurology, The, 2012, 11, 241-249.	10.2	390
475	Inverse-Consistent Symmetric Free Form Deformation. Lecture Notes in Computer Science, 2012, , 79-88.	1.3	20
476	Cross-sectional analysis using voxel or surface based cortical thickness methods: A comparison study. , 2011, , .		0
477	Familial Alzheimer's disease and inherited prion disease in the UK are poorly ascertained. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1054-1057.	1.9	13
478	Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 476-486.	1.9	508
479	Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 2011, 134, 2456-2477.	7.6	3,913
480	Normal Ageing. , 2011, , 43-57.		5
481	Brain MAPS: An automated, accurate and robust brain extraction technique using a template library. NeuroImage, 2011, 55, 1091-1108.	4.2	152
482	Algorithms, atrophy and Alzheimer's disease: Cautionary tales for clinical trials. NeuroImage, 2011, 57, 15-18.	4.2	69
483	LoAd: A locally adaptive cortical segmentation algorithm. NeuroImage, 2011, 56, 1386-1397.	4.2	81
484	A comparison of voxel and surface based cortical thickness estimation methods. NeuroImage, 2011, 57, 856-865.	4.2	163
485	Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology, 2011, 95, 579-593.	5.7	119
486	Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's disease. Neurobiology of Aging, 2011, 32, 1466-1476.	3.1	172

#	Article	IF	CITATIONS
487	Acceleration of cortical thinning in familial Alzheimer's disease. Neurobiology of Aging, 2011, 32, 1765-1773.	3.1	43
488	Impact of apolipoprotein É>4-cerebrospinal fluid beta-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment. , 2011, 7, 514-520.		26
489	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 270-279.	0.8	7,498
490	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 474.	0.8	176
491	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
492	Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurology, The, 2011, 10, 31-42.	10.2	530
493	Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE É>4 allele. Lancet Neurology, The, 2011, 10, 280-288.	10.2	273
494	Visual assessment of posterior atrophy development of a MRI rating scale. European Radiology, 2011, 21, 2618-2625.	4.5	299
495	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.7	17
496	A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies. Brain, 2011, 134, 2548-2564.	7.6	76
497	Basic Visual Function and Cortical Thickness Patterns in Posterior Cortical Atrophy. Cerebral Cortex, 2011, 21, 2122-2132.	2.9	69
498	Suspected early dementia. BMJ: British Medical Journal, 2011, 343, d5568-d5568.	2.3	5
499	Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain, 2011, 134, 2565-2581.	7.6	306
500	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain, 2011, 134, 293-300.	7.6	79
501	The clinical and neuroanatomical phenotype of FUS associated frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1405-1407.	1.9	32
502	Automated brain extraction using Multi-Atlas Propagation and Segmentation (MAPS). , 2011, , .		3
503	Structural neuroanatomy of tinnitus and hyperacusis in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 1274-1278.	1.9	62
504	An Event-Based Disease Progression Model and Its Application to Familial Alzheimer's Disease. Lecture Notes in Computer Science, 2011, 22, 748-759.	1.3	13

#	ARTICLE	IF	CITATIONS
505	Primary Grey Matter Loss. , 2011, , 59-135.		0
506	Volume changes in Alzheimer's disease and mild cognitive impairment: cognitive associations. European Radiology, 2010, 20, 674-682.	4.5	100
507	Does registration of serial MRI improve diagnosis of dementia?. Neuroradiology, 2010, 52, 987-995.	2.2	2
508	11C-PiB PET assessment of change in fibrillar amyloid-Î ² load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology, The, 2010, 9, 363-372.	10.2	674
509	The diagnosis of young-onset dementia. Lancet Neurology, The, 2010, 9, 793-806.	10.2	435
510	Fast free-form deformation using graphics processing units. Computer Methods and Programs in Biomedicine, 2010, 98, 278-284.	4.7	841
511	Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer's disease. International Journal of Geriatric Psychiatry, 2010, 25, 1119-1126.	2.7	15
512	Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1â€42. Annals of Neurology, 2010, 68, 825-834.	5.3	150
513	Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease. Movement Disorders, 2010, 25, 888-895.	3.9	19
514	Reduced Cortical Thickness in the Posterior Cingulate Gyrus is Characteristic of Both Typical and Atypical Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 20, 587-598.	2.6	87
515	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	2.5	347
516	Measuring disease progression in frontotemporal lobar degeneration. Neurology, 2010, 74, 666-673.	1.1	59
517	POD03 Distinct neuropsychological profiles correspond to distribution of cortical thinning in in inherited prion disease caused by insertional mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e42-e43.	1.9	0
518	The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 756-763.	1.9	105
519	Brain-water diffusion coefficients reflect the severity of inherited prion disease. Neurology, 2010, 74, 658-665.	1.1	7
520	Short echo time proton magnetic resonance spectroscopy in Alzheimer's disease: a longitudinal multiple time point study. Brain, 2010, 133, 3315-3322.	7.6	51
521	POMD01 Blinded analysis of conventional MRI in a cohort of pathologically confirmed parkinsonian illnesses. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e57-e57.	1.9	1
522	Onset and Progression of Pathologic Atrophy in Huntington Disease: A Longitudinal MR Imaging Study. American Journal of Neuroradiology, 2010, 31, 1036-1041.	2.4	90

#	Article	IF	CITATIONS
523	Pitfalls in the Use of Voxel-Based Morphometry as a Biomarker: Examples from Huntington Disease. American Journal of Neuroradiology, 2010, 31, 711-719.	2.4	94
524	The clinical use of structural MRI in Alzheimer disease. Nature Reviews Neurology, 2010, 6, 67-77.	10.1	1,505
525	Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease. NeuroImage, 2010, 51, 1345-1359.	4.2	224
526	Head size, age and gender adjustment in MRI studies: a necessary nuisance?. Neurolmage, 2010, 53, 1244-1255.	4.2	421
527	Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment. Neurobiology of Aging, 2010, 31, 1452-1462.e2.	3.1	70
528	An unbiased, staged, multicentre, validation strategy for Alzheimer's disease CSF tau levels. Experimental Neurology, 2010, 223, 432-438.	4.1	10
529	Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2010, 6, 212-220.	0.8	311
530	Atrophy patterns in Alzheimer's disease and semantic dementia: A comparison of FreeSurfer and manual volumetric measurements. NeuroImage, 2010, 49, 2264-2274.	4.2	97
531	Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection. NeuroImage, 2010, 50, 516-523.	4.2	125
532	Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neurolmage, 2010, 53, 1070-1076.	4.2	209
533	Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimer's Research and Therapy, 2010, 3, 1.	6.2	424
534	Nonlinear Elastic Spline Registration: Evaluation with Longitudinal Huntington's Disease Data. Lecture Notes in Computer Science, 2010, , 128-139.	1.3	1
535	A Framework for Using Diffusion Weighted Imaging to Improve Cortical Parcellation. Lecture Notes in Computer Science, 2010, 13, 534-541.	1.3	12
536	Increasing Power to Predict Mild Cognitive Impairment Conversion to Alzheimer's Disease Using Hippocampal Atrophy Rate and Statistical Shape Models. Lecture Notes in Computer Science, 2010, 13, 125-132.	1.3	18
537	Genetic Variability in CLU and Its Association with Alzheimer's Disease. PLoS ONE, 2010, 5, e9510.	2.5	52
538	A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology, 2009, 73, 2061-2070.	1.1	677
539	Presymptomatic Generalized Brain Atrophy in Frontotemporal Dementia Caused by <i>CHMP2B</i> Mutation. Dementia and Geriatric Cognitive Disorders, 2009, 27, 182-186.	1.5	17
540	Patterns of Cortical Thickness according to APOE Genotype in Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2009, 28, 461-470.	1.5	38

#	Article	IF	CITATIONS
541	Microglial activation and amyloid deposition in mild cognitive impairment. Neurology, 2009, 72, 56-62.	1.1	319
542	The heritability and genetics of frontotemporal lobar degeneration. Neurology, 2009, 73, 1451-1456.	1.1	416
543	The clinical profile of right temporal lobe atrophy. Brain, 2009, 132, 1287-1298.	7.6	277
544	Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology, 2009, 72, 1562-1569.	1.1	241
545	Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders. Current Alzheimer Research, 2009, 6, 144-151.	1.4	236
546	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology, 2009, 73, 935-940.	1.1	70
547	Hippocampal atrophy rates in Alzheimer disease. Neurology, 2009, 72, 999-1007.	1.1	315
548	Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurology, The, 2009, 8, 791-801.	10.2	856
549	Clinical application of measurement of hippocampal atrophy in degenerative dementias. Hippocampus, 2009, 19, 510-516.	1.9	30
550	Wholeâ€brain atrophy as a measure of progression in premanifest and early Huntington's disease. Movement Disorders, 2009, 24, 932-936.	3.9	49
551	Serial volumetric MRI in Parkinsonian disorders. Movement Disorders, 2009, 24, S691-8.	3.9	24
552	Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. Journal of Neurology, 2009, 256, 203-212.	3.6	50
553	Delusions in frontotemporal lobar degeneration. Journal of Neurology, 2009, 256, 600-7.	3.6	46
554	Structural imaging markers for therapeutic trials in Alzheimer's disease. Journal of Nutrition, Health and Aging, 2009, 13, 350-352.	3.3	13
555	HECTD2, a candidate susceptibility gene for Alzheimer's disease on 10q. BMC Medical Genetics, 2009, 10, 90.	2.1	11
556	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697
557	Imaging Biomarkers in Alzheimer's Disease. Annals of the New York Academy of Sciences, 2009, 1180, 20-27.	3.8	9
558	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. European Radiology, 2009, 19, 2826-2833.	4.5	88

#	Article	IF	CITATIONS
559	Conversion of amyloid positive and negative MCI to AD over 3 years. Neurology, 2009, 73, 754-760.	1.1	469
560	Visual rating of atrophy aids diagnostic accuracy. Nature Reviews Neurology, 2009, 5, 243-244.	10.1	2
561	A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiology of Aging, 2009, 30, 1711-1723.	3.1	294
562	Issues with threshold masking in voxel-based morphometry of atrophied brains. NeuroImage, 2009, 44, 99-111.	4.2	275
563	Comparison of phantom and registration scaling corrections using the ADNI cohort. NeuroImage, 2009, 47, 1506-1513.	4.2	54
564	Automated quantification of caudate atrophy by local registration of serial MRI: Evaluation and application in Huntington's disease. NeuroImage, 2009, 47, 1659-1665.	4.2	46
565	Pure Progressive Amnesia and the APPV717G Mutation. Alzheimer Disease and Associated Disorders, 2009, 23, 410-414.	1.3	9
566	Improved Maximum a Posteriori Cortical Segmentation by Iterative Relaxation of Priors. Lecture Notes in Computer Science, 2009, 12, 441-449.	1.3	7
567	Volumetric MRI and cognitive measures in Alzheimer disease. Journal of Neurology, 2008, 255, 567-574.	3.6	121
568	Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a runâ€in period increase efficiency?. Statistics in Medicine, 2008, 27, 3717-3731.	1.6	28
569	The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods. Journal of Magnetic Resonance Imaging, 2008, 27, 685-691.	3.4	2,553
570	Imaging cadavers: Cold FLAIR and noninvasive brain thermometry using CSF diffusion. Magnetic Resonance in Medicine, 2008, 59, 190-195.	3.0	46
571	Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurology, The, 2008, 7, 436-450.	10.2	146
572	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiology of Disease, 2008, 32, 412-419.	4.4	448
573	Neuropsychological correlates of whole brain atrophy in Alzheimer's disease. Neuropsychologia, 2008, 46, 1732-1737.	1.6	49
574	Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia, 2008, 46, 2152-2160.	1.6	93
575	Increased hippocampal atrophy rates in AD over 6 months using serial MR imaging. Neurobiology of Aging, 2008, 29, 1199-1203.	3.1	23
576	Intensity non-uniformity correction using N3 on 3-T scanners with multichannel phased array coils. NeuroImage, 2008, 39, 1752-1762.	4.2	128

#	Article	IF	CITATIONS
577	Ten simple rules for reporting voxel-based morphometry studies. NeuroImage, 2008, 40, 1429-1435.	4.2	221
578	A comparison of methods for the automated calculation of volumes and atrophy rates in the hippocampus. Neurolmage, 2008, 40, 1655-1671.	4.2	104
579	3D characterization of brain atrophy in Alzheimer's disease and mild cognitive impairment using tensor-based morphometry. NeuroImage, 2008, 41, 19-34.	4.2	149
580	Accuracy assessment of global and local atrophy measurement techniques with realistic simulated longitudinal Alzheimer's disease images. NeuroImage, 2008, 42, 696-709.	4.2	32
581	A plea for confidence intervals and consideration of generalizability in diagnostic studies. Brain, 2008, 132, e102-e102.	7.6	10
582	A distinct clinical, neuropsychological and radiological phenotype is associated with progranulin gene mutations in a large UK series. Brain, 2008, 131, 706-720.	7.6	222
583	Accuracy of dementia diagnosisa direct comparison between radiologists and a computerized method. Brain, 2008, 131, 2969-2974.	7.6	222
584	AN ALTERNATIVE METHOD FOR ESTIMATING EFFICACY OF THE AN1792 VACCINE FOR ALZHEIMER DISEASE. Neurology, 2008, 71, 697-698.	1.1	6
585	Tracking progression in frontotemporal lobar degeneration. Neurology, 2008, 71, 1445-1451.	1.1	74
586	Whole-brain atrophy rate in Alzheimer disease. Neurology, 2008, 70, 1836-1841.	1.1	94
587	Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease. American Journal of Neuroradiology, 2008, 29, 944-949.	2.4	162
588	The cultural context of visual hallucinations. Postgraduate Medical Journal, 2008, 84, 103-105.	1.8	1
589	Automatic classification of MR scans in Alzheimer's disease. Brain, 2008, 131, 681-689.	7.6	1,017
590	Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients. Radiology, 2008, 248, 590-598.	7.3	133
591	Mapping the progression of progranulin-associated frontotemporal lobar degeneration. Nature Clinical Practice Neurology, 2008, 4, 455-460.	2.5	45
592	Parietal Lobe Deficits in Frontotemporal Lobar Degeneration Caused by a Mutation in the Progranulin Gene. Archives of Neurology, 2008, 65, 506.	4.5	52
593	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. Neurology, 2007, 69, 1491-1497.	1.1	77
594	Application of Automated Medial Temporal Lobe Atrophy Scale to Alzheimer Disease. Archives of Neurology, 2007, 64, 849.	4.5	60

#	Article	IF	CITATIONS
595	A Systematic Review and Meta-Analysis of CSF Neurofilament Protein Levels as Biomarkers in Dementia. Neurodegenerative Diseases, 2007, 4, 185-194.	1.4	97
596	Correlations Between Apolipoprotein E ε4 Gene Dose and Whole Brain Atrophy Rates. American Journal of Psychiatry, 2007, 164, 916-921.	7.2	104
597	Longitudinal imaging in dementia. British Journal of Radiology, 2007, 80, S92-S98.	2.2	21
598	Structural magnetic resonance imaging-derived biomarkers for Alzheimer's disease. Biomarkers in Medicine, 2007, 1, 79-92.	1.4	4
599	Quantitative Magnetization Transfer Imaging in Alzheimer Disease. Radiology, 2007, 244, 832-837.	7.3	49
600	Amyloid, hypometabolism, and cognition in Alzheimer disease. Neurology, 2007, 68, 501-508.	1.1	470
601	Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. Archives of Neurology, 2007, 64, 1023.	4.5	67
602	The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology, 2007, 68, 624-624.	1.1	6
603	Symptoms of Memory Loss as Predictors of Cognitive Impairment?. Alzheimer Disease and Associated Disorders, 2007, 21, 101-106.	1.3	12
604	Automated Measurement of Hippocampal Atrophy Using Fluid-Registered Serial MRI in AD and Controls. Journal of Computer Assisted Tomography, 2007, 31, 581-587.	0.9	18
605	Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD. Neurobiology of Aging, 2007, 28, 20-28.	3.1	72
606	Automatic calculation of hippocampal atrophy rates using a hippocampal template and the boundary shift integral. Neurobiology of Aging, 2007, 28, 1657-1663.	3.1	40
607	Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. Neurolmage, 2007, 34, 1036-1041.	4.2	39
608	VBM signatures of abnormal eating behaviours in frontotemporal lobar degeneration. NeuroImage, 2007, 35, 207-213.	4.2	122
609	Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: Cross-validation of BSI, SIENA and SIENAX. NeuroImage, 2007, 36, 1200-1206.	4.2	100
610	Word-finding difficulty: a clinical analysis of the progressive aphasias. Brain, 2007, 131, 8-38.	7.6	135
611	Cerebral Atrophy Measurement in Clinically Isolated Syndromes and Relapsing Remitting Multiple Sclerosis: A Comparison of Registrationâ€Based Methods. Journal of Neuroimaging, 2007, 17, 61-68.	2.0	49
612	Structural imaging in the dementias. Psychiatry (Abingdon, England), 2007, 6, 503-507.	0.2	1

NICK C FOX

#	Article	IF	CITATIONS
613	Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurology, The, 2007, 6, 501-512.	10.2	314
614	MRI derived brain atrophy in PSP and MSA-P. Journal of Neurology, 2007, 254, 478-481.	3.6	45
615	Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: Sample size estimates. Journal of Neurology, 2007, 254, 1588-94.	3.6	44
616	Correlations Between Apolipoprotein E ε4 Gene Dose and Whole Brain Atrophy Rates. American Journal of Psychiatry, 2007, 164, 916.	7.2	29
617	Accuracy Assessment of Global and Local Atrophy Measurement Techniques with Realistic Simulated Longitudinal Data. , 2007, 10, 785-792.		5
618	Magnetization transfer ratio in Alzheimer disease: comparison with volumetric measurements. American Journal of Neuroradiology, 2007, 28, 965-70.	2.4	36
619	Phenomenological Model of Diffuse Global and Regional Atrophy Using Finite-Element Methods. IEEE Transactions on Medical Imaging, 2006, 25, 1417-1430.	8.9	32
620	Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. NeuroImage, 2006, 31, 627-640.	4.2	198
621	Cerebral atrophy measurements using Jacobian integration: Comparison with the boundary shift integral. NeuroImage, 2006, 32, 159-169.	4.2	60
622	Posterior Cingulate Neurometabolite Profiles and Clinical Phenotype in Frontotemporal Dementia. Cognitive and Behavioral Neurology, 2006, 19, 185-189.	0.9	12
623	New developments in mild cognitive impairment and Alzheimer's disease. Current Opinion in Neurology, 2006, 19, 552-558.	3.6	25
624	Combining short interval MRI in Alzheimer's disease. Journal of Neurology, 2006, 253, 1147-1153.	3.6	43
625	Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurology, The, 2006, 5, 828-834.	10.2	292
626	Do symptoms of memory impairment correspond to cognitive impairment: a cross sectional study of a clinical cohort. International Journal of Geriatric Psychiatry, 2006, 21, 1206-1212.	2.7	20
627	Regional brain volumes distinguish PSP, MSAâ€P, and PD: MRIâ€based clinicoâ€radiological correlations. Movement Disorders, 2006, 21, 989-996.	3.9	119
628	Magnetic resonance imaging measures of brain atrophy in multiple sclerosis. Journal of Magnetic Resonance Imaging, 2006, 23, 605-618.	3.4	103
629	Amyloid load and cerebral atrophy in Alzheimer's disease: An ¹¹ Câ€PIB positron emission tomography study. Annals of Neurology, 2006, 60, 145-147.	5.3	178
630	Measurements of the Amygdala and Hippocampus in Pathologically Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Archives of Neurology, 2006, 63, 1434.	4.5	139

#	Article	IF	CITATIONS
631	Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy. Brain, 2006, 129, 1040-1049.	7.6	192
632	MRS shows abnormalities before symptoms in familial Alzheimer disease. Neurology, 2006, 66, 718-722.	1.1	113
633	A second family with familial AD and the V717L APP mutation has a later age at onset. Neurology, 2006, 66, 611-612.	1.1	11
634	Increased rate of whole-brain atrophy over 6 months in early Huntington disease. Neurology, 2006, 67, 694-696.	1.1	45
635	Apolipoprotein E Genotype Modifies the Phenotype of Alzheimer Disease. Archives of Neurology, 2006, 63, 155.	4.5	65
636	The effect of <i>APOE</i> genotype on clinical phenotype in Alzheimer disease. Neurology, 2006, 67, 526-527.	1.1	85
637	Simulation of Acquisition Artefacts in MR Scans: Effects on Automatic Measures of Brain Atrophy. Lecture Notes in Computer Science, 2006, 9, 272-280.	1.3	6
638	Simulation of Local and Global Atrophy in Alzheimer's Disease Studies. Lecture Notes in Computer Science, 2006, 9, 937-945.	1.3	4
639	Visual Assessment of Atrophy on Magnetic Resonance Imaging in the Diagnosis of Pathologically Confirmed Young-Onset Dementias. Archives of Neurology, 2005, 62, 1410.	4.5	101
640	Brain biopsy in dementia. Brain, 2005, 128, 2016-2025.	7.6	127
641	Measuring atrophy in Alzheimer disease. Neurology, 2005, 65, 119-124.	1.1	155
642	Clinical effects of AÎ ² immunization (AN1792) in patients with AD in an interrupted trial. Neurology, 2005, 64, 1553-1562.	1.1	1,258
643	Effects of AÎ ² immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology, 2005, 64, 1563-1572.	1.1	527
644	Can the frontal assessment battery (FAB) differentiate bradykinetic rigid syndromes? Relation of the FAB to formal neuropsychological testing. Neurocase, 2005, 11, 274-282.	0.6	68
645	Does Alzheimer's Disease Affect Hippocampal Asymmetry? Evidence from a Cross-Sectional and Longitudinal Volumetric MRI Study. Dementia and Geriatric Cognitive Disorders, 2005, 19, 338-344.	1.5	83
646	A Volumetric Magnetic Resonance Imaging Study of the Amygdala in Frontotemporal Lobar Degeneration and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2005, 20, 238-244.	1.5	43
647	Mapping the onset and progression of atrophy in familial frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, 162-168.	1.9	33
648	Survival in Alzheimer Disease—Reply. Archives of Neurology, 2005, 62, 689.	4.5	0

#	Article	IF	CITATIONS
649	Differential Regional Atrophy of the Cingulate Gyrus in Alzheimer Disease: A Volumetric MRI Study. Cerebral Cortex, 2005, 16, 1701-1708.	2.9	131
650	Magnetic Resonance Imaging Signatures of Tissue Pathology in Frontotemporal Dementia. Archives of Neurology, 2005, 62, 1402.	4.5	132
651	Sporadic and Familial Dementia With Ubiquitin-Positive Tau-Negative Inclusions. Archives of Neurology, 2005, 62, 1097.	4.5	26
652	Knight's move thinking? Mild cognitive impairment in a chess player. Neurocase, 2005, 11, 26-31.	0.6	10
653	A decade of pre-diagnostic assessment in a case of familial Alzheimer's disease: tracking progression from asymptomatic to MCI and dementia. Neurocase, 2005, 11, 56-64.	0.6	20
654	Quantitative MRI measurement of superior cerebellar peduncle in progressive supranuclear palsy. Neurology, 2005, 64, 675-679.	1.1	168
655	An Inverse Problem Approach to the Estimation of Volume Change. Lecture Notes in Computer Science, 2005, 8, 616-623.	1.3	4
656	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S591-S591.	4.3	1
657	Longitudinal Patterns of Regional Change on Volumetric MRI in Frontotemporal Lobar Degeneration. Dementia and Geriatric Cognitive Disorders, 2004, 17, 307-310.	1.5	70
658	Pathological substrate for regional distribution of increased atrophy rates in progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry, 2004, 75, 1772-1775.	1.9	14
659	Voxel-Based Morphometry in Tau-Positive and Tau-Negative Frontotemporal Lobar Degenerations. Neurodegenerative Diseases, 2004, 1, 225-230.	1.4	21
660	A presenilin 1 R278I mutation presenting with language impairment. Neurology, 2004, 63, 1702-1704.	1.1	51
661	The Natural History of Alzheimer Disease. Archives of Neurology, 2004, 61, 1743.	4.5	56
662	Structural imaging in the dementias. Psychiatry (Abingdon, England), 2004, 3, 22-26.	0.2	0
663	The analysis of repeated â€~direct' measures of change illustrated with an application in longitudinal imaging. Statistics in Medicine, 2004, 23, 3275-3286.	1.6	43
664	Using nine degrees-of-freedom registration to correct for changes in voxel size in serial MRI studies. Magnetic Resonance Imaging, 2004, 22, 993-999.	1.8	14
665	The application of serial MRI analysis techniques to the study of cerebral atrophy in late-onset dementia. Medical Image Analysis, 2004, 8, 69-79.	11.6	15
666	Measuring Progression in Alzheimer's Disease using Serial MRI: 4D MRI. , 2004, , 61-74.		0

#	Article	IF	CITATIONS
667	Biomarkers and surrogates. NeuroRx, 2004, 1, 181-181.	6.0	33
668	An automated algorithm for the computation of brain volume change from sequential MRIs using an iterative principal component analysis and its evaluation for the assessment of whole-brain atrophy rates in patients with probable Alzheimer's disease. NeuroImage, 2004, 22, 134-143.	4.2	48
669	Correction of differential intensity inhomogeneity in longitudinal MR images. NeuroImage, 2004, 23, 75-83.	4.2	113
670	Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. NeuroImage, 2004, 23, 663-669.	4.2	139
671	Differentiating AD from aging using semiautomated measurement of hippocampal atrophy rates. NeuroImage, 2004, 23, 574-581.	4.2	101
672	Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. NeuroImage, 2004, 23, 708-716.	4.2	522
673	O4-05-08 Effects of A-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. Neurobiology of Aging, 2004, 25, S84-S85.	3.1	3
674	Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet, The, 2004, 363, 392-394.	13.7	367
675	Fluid Deformation of Serial Structural MRI for Low-Grade Glioma Growth Analysis. Lecture Notes in Computer Science, 2004, , 1055-1056.	1.3	2
676	Computer-assisted imaging to assess brain structure in healthy and diseased brains. Lancet Neurology, The, 2003, 2, 79-88.	10.2	354
677	Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. International Journal of Geriatric Psychiatry, 2003, 18, 67-72.	2.7	84
678	Delineating the sites and progression of in vivo atrophy in multiple system atrophy using fluid-registered MRI. Movement Disorders, 2003, 18, 955-958.	3.9	19
679	Assessing the onset of structural change in familial Alzheimer's disease. Annals of Neurology, 2003, 53, 181-188.	5.3	152
680	Cerebrospinal fluid S100B correlates with brain atrophy in Alzheimer's disease. Neuroscience Letters, 2003, 336, 167-170.	2.1	99
681	Change in rates of cerebral atrophy over time in early-onset Alzheimer's disease: longitudinal MRI study. Lancet, The, 2003, 362, 1121-1122.	13.7	190
682	Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 1371-1381.	1.9	69
683	Nothing to Say, Something to Sing: Primary Progressive Dynamic Aphasia. Neurocase, 2003, 9, 140-155.	0.6	60
684	A Longitudinal Study of Brain Volume Changes in Normal Aging Using Serial Registered Magnetic Resonance Imaging. Archives of Neurology, 2003, 60, 989.	4.5	736

#	Article	IF	CITATIONS
685	Transient ischaemic attacks are associated with increased rates of global cerebral atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 213-216.	1.9	44
686	Development of selective verbal memory impairment secondary to a left thalamic infarct: a longitudinal case study. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 255-257.	1.9	24
687	Early onset familial Alzheimer's disease. Neurology, 2003, 60, 235-239.	1.1	292
688	Neurofilament inclusion body disease: a new proteinopathy?. Brain, 2003, 126, 2291-2303.	7.6	176
689	Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4703-4707.	7.1	613
690	Differing patterns of temporal atrophy in Alzheimer's disease and semantic dementia. Neurology, 2002, 58, 838-838.	1.1	23
691	Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology, 2002, 59, 1108-1110.	1.1	76
692	Epilepsy presenting as AD: Neuroimaging, electroclinical features, and response to treatment. Neurology, 2002, 58, 298-301.	1.1	72
693	Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 141-147.	1.9	138
694	Genetics of the dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 27ii-31.	1.9	40
695	Automatic Differentiation of Anatomical Patterns in the Human Brain: Validation with Studies of Degenerative Dementias. NeuroImage, 2002, 17, 29-46.	4.2	399
696	Clinical features of frontotemporal dementia due to the intronic <i>tau</i> 10 ⁺¹⁶ mutation. Neurology, 2002, 58, 1161-1168.	1.1	85
697	Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurology, The, 2002, 1, 13-21.	10.2	337
698	Automated Hippocampal Segmentation by Regional Fluid Registration of Serial MRI: Validation and Application in Alzheimer's Disease. NeuroImage, 2001, 13, 847-855.	4.2	124
699	Imaging of onset and progression of Alzheimer's disease with voxel-compression mapping of serial magnetic resonance images. Lancet, The, 2001, 358, 201-205.	13.7	414
700	Haemodialysis and Cerebral Oedema. Nephron, 2001, 87, 143-147.	1.8	73
701	Autopsy-Confirmed Familial Early-Onset Alzheimer Disease Caused by the L153V Presenilin 1 Mutation. Archives of Neurology, 2001, 58, 953.	4.5	26
702	Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Annals of Neurology, 2001, 49, 433-442	5.3	641

#	Article	IF	CITATIONS
703	Long-term retrograde amnesiaâ \in the crucial role of the hippocampus. Neuropsychologia, 2001, 39, 151-172.	1.6	192
704	Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology, 2001, 56, 1386-1388.	1.1	199
705	Rates of global and regional cerebral atrophy in AD and frontotemporal dementia. Neurology, 2001, 57, 1756-1763.	1.1	200
706	Automated Hippocampal Segmentation by Regional Fluid Registration of Serial MRI: Validation and Application in Alzheimer.s Disease. Lecture Notes in Computer Science, 2001, , 1298-1299.	1.3	0
707	Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging. American Journal of Neuroradiology, 2001, 22, 1483-9.	2.4	236
708	Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease. Annals of Neurology, 2001, 49, 433-42.	5.3	201
709	Alzheimer's disease due to an intronic presenilin-1 (PSEN1 intron 4) mutation. Brain, 2000, 123, 894-907.	7.6	34
710	Mere forgetfulness or early Alzheimer's disease?. Annals of Neurology, 2000, 47, 419-420.	5.3	6
711	Seeing what Alzheimer saw—with magnetic resonance microscopy. Nature Medicine, 2000, 6, 20-21.	30.7	7
712	Progressive cerebral atrophy in MS: A serial study using registered, volumetric MRI. Neurology, 2000, 55, 1242-1243.	1.1	4
713	Progressive cerebral atrophy in MS. Neurology, 2000, 54, 807-812.	1.1	199
714	Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology, 2000, 54, 1689-1691.	1.1	176
715	Intracranial Volume and Alzheimer Disease. Archives of Neurology, 2000, 57, 220.	4.5	115
716	A Volumetric Study of Hippocampus and Amygdala in Depressed Patients With Subjective Memory Problems. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 493-498.	1.8	109
717	Using Serial Registered Brain Magnetic Resonance Imaging to Measure Disease Progression in Alzheimer Disease. Archives of Neurology, 2000, 57, 339.	4.5	346
718	Description of a simple test for CADASIL disease and determination of mutation frequencies in sporadic ischaemic stroke and dementia patients. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 652-654.	1.9	29
719	A Volumetric Study of Hippocampus and Amygdala in Depressed Patients With Subjective Memory Problems. Journal of Neuropsychiatry and Clinical Neurosciences, 2000, 12, 493-498.	1.8	30
720	Correlation between rates of brain atrophy and cognitive decline in AD. Neurology, 1999, 52, 1687-1687.	1.1	305

#	Article	IF	CITATIONS
721	Pathogenic presenilin 1 mutations (P436S & I143F) in early-onset Alzheimer's disease in the UK. , 1999, 13, 256-256.		22
722	Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet, The, 1999, 353, 2125.	13.7	145
723	Diagnosis of early Alzheimer's disease. Revue Neurologique, 1999, 155 Suppl 4, S33-7.	1.5	5
724	CANDID?counselling and diagnosis in dementia: a national telemedicine service supporting the care of younger patients with dementia. , 1998, 13, 381-388.		33
725	MR image texture analysis applied to the diagnosis and tracking of Alzheimer's disease. IEEE Transactions on Medical Imaging, 1998, 17, 475-478.	8.9	152
726	Chromosome 14Âfamilial Alzheimer's disease: the clinical and neuropathological characteristics of a family with a leucineright-arrowserine (L250S) substitution at codon 250Âof the presenilin 1Âgene. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 64, 44-49.	1.9	49
727	Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease. A longitudinal prospective study. Brain, 1998, 121, 1631-1639.	7.6	222
728	Modeling Brain Deformations in Alzheimer Disease by Fluid Registration of Serial 3D MR Images. Journal of Computer Assisted Tomography, 1998, 22, 838-843.	0.9	217
729	Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain, 1997, 120, 491-501.	7.6	84
730	The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Transactions on Medical Imaging, 1997, 16, 623-629.	8.9	335
731	Dementia associated with haemochromatosis: a report of two cases. European Journal of Neurology, 1997, 4, 318-322.	3.3	14
732	Interactive algorithms for the segmentation and quantitation of 3-D MRI brain scans. Computer Methods and Programs in Biomedicine, 1997, 53, 15-25.	4.7	253
733	Brain atrophy progression measured from registered serial MRI: Validation and application to alzheimer's disease. Journal of Magnetic Resonance Imaging, 1997, 7, 1069-1075.	3.4	304
734	Cerebral and cerebellar atrophy on serial magnetic resonance imaging in an initially symptom free subject at risk of familial prion disease. BMJ: British Medical Journal, 1997, 315, 856-857.	2.3	14
735	Atrophy of the Hippocampal Formation in Early Familial Alzheimer's Disease. Annals of the New York Academy of Sciences, 1996, 777, 226-232.	3.8	57
736	Clinical Features of Sporadic and Familial Alzheimer's Disease. Experimental Neurology, 1996, 5, 393-397.	1.7	26
737	Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet, The, 1996, 348, 94-97.	13.7	351
738	Incomplete penetrance of familial Alzheimer's disease in a pedigree with a novel presenilin-1 gene mutation. Lancet, The, 1996, 347, 1560.	13.7	77

#	Article	IF	CITATIONS
739	Non-Alzheimer dementias in young patients. British Journal of Psychiatry, 1996, 168, 384-385.	2.8	19
740	Assessing patterns and rates of brain atrophy by serial magnetic resonance imaging: A segmentation, registration, display and quantification procedure. Lecture Notes in Computer Science, 1996, , 417-428.	1.3	1
741	Protein Folding, Nucleation Phenomena and Delayed Neurodegeneration in Alzheimer's Disease. Reviews in the Neurosciences, 1996, 7, 21-8.	2.9	10
742	Presymptomatic hippocampal atrophy in Alzheimer's disease. Brain, 1996, 119, 2001-2007.	7.6	579
743	Accurate Registration of Serial 3D MR Brain Images and Its Application to Visualizing Change in Neurodegenerative Disorders. Journal of Computer Assisted Tomography, 1996, 20, 1012-1022.	0.9	140
744	The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families. Nature Genetics, 1995, 11, 219-222.	21.4	461
745	Comparison of nasal pressure support ventilation with nasal intermittent positive pressure ventilation in patients with nocturnal hypoventilation. European Respiratory Journal, 1993, 6, 364-70.	6.7	36
746	NeuroGrid: Using Grid Technology to Advance Neuroscience. , 0, , .		17
747	Cognitive Impairment and Dementia. , 0, , 245-288.		5
748	Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease. Alzheimer's and Dementia, 0, , .	0.8	2
749	Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials. Frontiers in Aging	3.4	3